[HTML][HTML] A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP. 664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing …
…, J Korzun, M Golabek, K de Los Reyes, TJ Ketas… - PLoS …, 2013 - journals.plos.org
A desirable but as yet unachieved property of a human immunodeficiency virus type 1 (HIV-1)
vaccine candidate is the ability to induce broadly neutralizing antibodies (bNAbs). One …
vaccine candidate is the ability to induce broadly neutralizing antibodies (bNAbs). One …
HIV-1 neutralizing antibodies induced by native-like envelope trimers
RW Sanders, MJ van Gils, R Derking, D Sok, TJ Ketas… - Science, 2015 - science.org
INTRODUCTION A major goal of HIV-1 vaccine development is to identify immunogens capable
of inducing protective titers of broadly neutralizing antibodies (bNAbs) against circulating…
of inducing protective titers of broadly neutralizing antibodies (bNAbs) against circulating…
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus–cell fusion
…, SM Schader, Q Hu, TJ Ketas, M Lu, PA Marx, J Dufour… - Nature, 2005 - nature.com
Human immunodeficiency virus type 1 (HIV-1) continues to spread, principally by heterosexual
sex, but no vaccine is available 1 . Hence, alternative prevention methods are needed to …
sex, but no vaccine is available 1 . Hence, alternative prevention methods are needed to …
HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits
…, B He, M Shan, SC Ball, WB Dyer, TJ Ketas… - Nature …, 2009 - nature.com
Contact-dependent communication between immune cells generates protection but also
facilitates viral spread. Here we found that macrophages formed long-range actin-propelled …
facilitates viral spread. Here we found that macrophages formed long-range actin-propelled …
Structural and biological mimicry of protein surface recognition by α/β-peptide foldamers
WS Horne, LM Johnson, TJ Ketas… - Proceedings of the …, 2009 - National Acad Sciences
Unnatural oligomers that can mimic protein surfaces offer a potentially useful strategy for
blocking biomedically important protein-protein interactions. Here we evaluate an approach …
blocking biomedically important protein-protein interactions. Here we evaluate an approach …
Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140
A Trkola, TJ Ketas, KA Nagashima, L Zhao… - Journal of …, 2001 - Am Soc Microbiol
CCR5 serves as a requisite fusion coreceptor for clinically relevant strains of human
immunodeficiency virus type 1 (HIV-1) and provides a promising target for antiviral therapy. However…
immunodeficiency virus type 1 (HIV-1) and provides a promising target for antiviral therapy. However…
A Native-Like SOSIP.664 Trimer Based on an HIV-1 Subtype B env Gene
…, M Golabek, K de Los Reyes, TJ Ketas… - Journal of …, 2015 - Am Soc Microbiol
Recombinant trimeric mimics of the human immunodeficiency virus type 1 (HIV-1) envelope
glycoprotein (Env) spike should expose as many epitopes as possible for broadly …
glycoprotein (Env) spike should expose as many epitopes as possible for broadly …
[HTML][HTML] Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva
TJ Ketas, D Chaturbhuj, VMC Portillo… - Pathogens and …, 2021 - ncbi.nlm.nih.gov
The approved Pfizer and Moderna mRNA vaccines are well known to induce serum antibody
responses to the SARS-CoV-2 Spike (S)-protein. However, their abilities to elicit mucosal …
responses to the SARS-CoV-2 Spike (S)-protein. However, their abilities to elicit mucosal …
Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency
…, M Veneziano, F Bonelli, TJ Ketas… - Proceedings of the …, 2009 - National Acad Sciences
Peptides derived from the heptad repeat 2 (HR2) region of the HIV fusogenic protein gp41
are potent inhibitors of viral infection, and one of them, enfuvirtide, is used for the treatment of …
are potent inhibitors of viral infection, and one of them, enfuvirtide, is used for the treatment of …
[HTML][HTML] T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers
…, TM Styles, CF Quarnstrom, KA Walter, TJ Ketas… - Nature medicine, 2020 - nature.com
Recent efforts toward an HIV vaccine focus on inducing broadly neutralizing antibodies, but
eliciting both neutralizing antibodies (nAbs) and cellular responses may be superior. Here, …
eliciting both neutralizing antibodies (nAbs) and cellular responses may be superior. Here, …